Prostate Cancer Trial, Recruiting NCT03805919 Sponsor: National Cancer Institute (NCI) Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT03805919
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between the ages of 30 and 75 years old
  • People who have a confirmed harmful or likely harmful genetic variant in a prostate cancer risk-related gene, identified by a certified laboratory — this includes variants in genes such as BRCA1, BRCA2, Lynch syndrome-related genes (MLH1, MSH2, MSH6, PMS2, EPCAM), and others including HOXB13, ATM, NBN, TP53, CHEK2, PALB2, RAD51C, RAD51D, BRIP1, or certain FANC genes (confirm with trial site for the full list)
  • People whose doctors expect them to survive more than 5 years if they have been diagnosed with another type of cancer
  • People who are able to understand the trial and are willing to sign a written consent form

Who may not be able to join:

  • People who have previously been diagnosed with or treated for prostate cancer
  • People who are unable to fit inside an MRI scanner, as determined by the radiology team
  • People who have a known allergy to MRI contrast dye
  • People who have a pacemaker, cerebral aneurysm clips, shrapnel injuries, or any implanted electronic device
  • People who have active medical or psychological conditions that the principal investigator determines could increase risk or prevent them from giving informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Fatima H Karzai, M.D., National Cancer Institute (NCI)

Phone: (240) 858-3148

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
27 March 2019
Est. completion
1 January 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Natural history of high genetic risk for prostate cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov